Siemens third quarter included a bit of good news and a bit of bad.

The group made the biggest contribution to the bottom line – a 9 percent boost to $686 million, a 2 percent jump in orders, and in keeping with expectations, according to Reuters.

But other parts of the Siemens empire proved a drag and drove shares down, according to the news agency.

Calling the financials “fully on track for another strong year,” the company detailed in a statement that revenue was up 8 percent from the year-ago quarter, with orders coming in 6 percent lower, “due to sharply lower volume from large orders at Power and Gas and at Siemens Gamesa Renewable Energy.”

Despite certain issues that posed present challenges, Joe Kaeser, president and chief executive officer of Siemens AG, stated that, “our global team delivered a solid quarter with revenue up 8 percent and net income growing by 7 percent. Our digital enterprise business impressively underscored its leading position in the market. We are fully on track with Vision 2020 and for another strong year,"

He did confess on the August 3 conference call, however, that “everything is not perfect at Siemens," especially in reference to the so-called “Crimea affair.”

The affair involved four giant gas turbines sent legally to Russia that wound up illegally in the Crimea – which is under energy-tech sanctions, according to the Washington Post.

In 2014, the EU leveled economic sanctions on Russia due to its “annexation” of Ukraine's Crimean region, noted the paper.

"The Crimea affair has cost us much time and effort,” said Kaeser, adding, “We have to ask ourselves what this means for our future business processes and relationships."

A review of the company's dealings could cost it as much as 200 million euros in sales, according to the CEO, whose contract was today lengthened to 2021.

He called the turbine maneuver “unacceptable” and a contract breach “in criminal fashion.”

But he added that “it would be disproportionate to put an entire country, including loyal and reliable customers, under blanket suspicion.”

The customers he mentioned included the Russian railway system, Novatek and Gazprom.

The future of the Healthineers has been the subject of ongoing debate by investors for some time – ever since news that the intention was to list it broke in November, 2016.

At that time no firm details were announced for the group – which has been valued as high as $47 billion.

According to board member Michael Sen – tasked with the responsibility for the Healthineers – the group should have its “own currency” as it moves away from its imaging core more toward “molecular diagnosis” and “patient self-managment,” according to Reuters.

Although no new acquisitions or mergers are officially in its sights at the moment, he said on the call that, “the equity story begins with a highly attractive portfolio, which we already have."

Sen hinted that there were a number of attractive aspects to listing the entity in the U.S. and not Germany.

"Most peer group companies... are listed in the USA," he explained. "One has to ask where will one get the best research and coverage ... and sufficient market-making capacity and liquidity."

That said, listing in the U.S. does have a downside, according to Kaeser, at least.

Siemens had already announced in February the possibility that it would list the Healthineers in the U.S. and not Europe. “We don't have a final view on this yet, but we are looking at it very closely," Kaeser.

But there was a possible change of heart in early March, when Kaeser told Swiss newspaper Finanz and Wirtschaft that “under President Donald Trump” he “will have to think twice” about where to list the health care unit, mentioning Frankfurt and Hong Kong as possibilities.